Zu den Inhalten springen

Preclinical Imaging Research Center and Core Facility

The main focus of AMIR is multimodal imaging for pre-clinical and translational research. Our work is dedicated to the fusion of cellular research and clinical projects in development and implementation of novel and advanced techniques for small animal imaging. Modalities used include in vivo magnetic resonance imaging (MRI), small animal Ultrasound, optical imaging and µCT with a focus on photon counting techniques.

AMIR-CF is a certified Core Facility and co-funded by the Medical Faculty of the University Freiburg. It is furthermore registered at the RIsources portal of the DFG. The goal of AMIR-CF is to provide innovative preclinical imaging technology and research tools for our partners in the University and beyond. Usage of our facilites is possible in service- and in self-responsible- operation mode.

Equipment of the Research Group AMIR

The small animal imaging research group AMIR currently runs 3 dedicated in vivo MRI systems, an NMR spectrometer with in vitro high resolution imaging option, a mouse/rat Ultrasound, an in vivo small animal µCT, and an in vitro photon counting µCT. In addtion a small histology lab with a cryotome and microscopy is availabe. These research facilities are located in the basement of the Neuro Center and the 3rd floor of the IMITATE research building.

All systems are in principle accessible for external researchers as well via the Core Facility AMIR-CF.

Within the SFB 850 AMIR runs the core facility project Z2 “Imaging” in cooperation with the Dept. of Haematology and Oncology and the Dept. of Nuclearmedicine. It offers small animal imaging support and advice employing bioluminescence, micro PET and MRI techniques.

BrainLinks-BrainTools aims to develop medical technology that directly interacts with the nervous system. For this purpose, it unites the life sciences, engineering, and clinical applications. BrainLinks-BrainTools is a Cluster of Excellence, funded since 2012 within the German Excellence Initiative

NANOTRANSMED is a European project, led by a french-german-swiss consortium and cofinanced by the INTERREG VA Upper Rhine Programme. NANOTRANSMED enables French, German and Swiss scientists to develop together applications and innovations in nanomedicine. On the basis of new approaches, made possible by the use of nano-objects (probes, smart implants …), it is now possible to create innovative and efficient solutions meeting major issues regarding patients’ care. The NANOTRANSMED consortium focuses in particular on issues concerning early, reliable and fast diagnosis but also personalized treatment of diseases such as cancers and inflammation as well as issues regarding nosocomial infections contracted by 5% of hospitalized patients.


The Research Program Translational Cancer Research ,  is based on the German Cancer Research Center (DKFZ) within the National Center for Tumor Diseases (NCT) Heidelberg  and  has  its  focus on the transfer of approaches in the  prevention,  diagnosis  and  treatment of cancer to clinical application.